Overview

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Status:
Terminated

Trial end date:
2004-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma US, Inc.

Treatments:

N-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl)-2-phenylethenesulfonamide